This Author published in this journals
All Journal Narra J Narra X
Claim Missing Document
Check
Articles

Found 3 Documents
Search

Monkeypox: Immune response, vaccination and preventive efforts Youdiil Ophinni; Andri Frediansyah; Salin Sirinam; Dewi Megawati; Ana M. Stoian; Seyi S. Enitan; Richard Y. Akele; Ranjit Sah; Krit Pongpirul; Ziad Abdeen; Sevda Aghayeva; Aamer Ikram; Yohannes Kebede; Uwe Wollina; Kannan Subbaram; Ai Koyanagi; Abdulwahed Al Serouri; H. Blaise Nguendo-Yongsi; Jeffrey Edwards; Dina E. Sallam; Yousef Khader; Sandro G. Viveiros-Rosa; Ziad A. Memish; Mehrdad Amir-Behghadami; Sandro Vento; Marius Rademaker; Malik Sallam
Narra J Vol. 2 No. 3 (2022): December 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i3.90

Abstract

Infectious threats to humans are continuously emerging. The 2022 worldwide monkeypox outbreak is the latest of these threats with the virus rapidly spreading to 106 countries by the end of September 2022. The burden of the ongoing monkeypox outbreak is manifested by 68,000 cumulative confirmed cases and 26 deaths. Although monkeypox is usually a self-limited disease, patients can suffer from extremely painful skin lesions and complications can occur with reported mortalities. The antigenic similarity between the smallpox virus (variola virus) and monkeypox virus can be utilized to prevent monkeypox using smallpox vaccines; treatment is also based on antivirals initially designed to treat smallpox. However, further studies are needed to fully decipher the immune response to monkeypox virus and the immune evasion mechanisms. In this review we provide an up-to-date discussion of the current state of knowledge regarding monkeypox virus with a special focus on innate immune response, immune evasion mechanisms and vaccination against the virus.
Monkeypox: Immune response, vaccination and preventive efforts Youdiil Ophinni; Andri Frediansyah; Salin Sirinam; Dewi Megawati; Ana M. Stoian; Seyi S. Enitan; Richard Y. Akele; Ranjit Sah; Krit Pongpirul; Ziad Abdeen; Sevda Aghayeva; Aamer Ikram; Yohannes Kebede; Uwe Wollina; Kannan Subbaram; Ai Koyanagi; Abdulwahed Al Serouri; H. Blaise Nguendo-Yongsi; Jeffrey Edwards; Dina E. Sallam; Yousef Khader; Sandro G. Viveiros-Rosa; Ziad A. Memish; Mehrdad Amir-Behghadami; Sandro Vento; Marius Rademaker; Malik Sallam
Narra J Vol. 2 No. 3 (2022): December 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i3.90

Abstract

Infectious threats to humans are continuously emerging. The 2022 worldwide monkeypox outbreak is the latest of these threats with the virus rapidly spreading to 106 countries by the end of September 2022. The burden of the ongoing monkeypox outbreak is manifested by 68,000 cumulative confirmed cases and 26 deaths. Although monkeypox is usually a self-limited disease, patients can suffer from extremely painful skin lesions and complications can occur with reported mortalities. The antigenic similarity between the smallpox virus (variola virus) and monkeypox virus can be utilized to prevent monkeypox using smallpox vaccines; treatment is also based on antivirals initially designed to treat smallpox. However, further studies are needed to fully decipher the immune response to monkeypox virus and the immune evasion mechanisms. In this review we provide an up-to-date discussion of the current state of knowledge regarding monkeypox virus with a special focus on innate immune response, immune evasion mechanisms and vaccination against the virus.
Essential oils for COVID-19 management: A systematic review of randomized controlled trials Teuku F. Duta; Diva R. Rizki; Agnia Purnama; Marius Rademaker; Uwe Wollina; Yogesh Acharya; Ziad Abdeen; Sandro G. V. Rosa; Henning B. Nielsen; Kannan Subbaram
Narra X Vol. 1 No. 2 (2023): August 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narrax.v1i2.84

Abstract

Essential oils can be a beneficial adjuvant therapy in managing coronavirus disease 2019 (COVID-19). This systematic review aims to evaluate the efficacy of essential oils in ameliorative COVID-19-related symptoms. Published studies reporting the efficacy of essential oils as adjuvant therapy for COVID-19 were screened on Scillit, Scopus, SciFinder, and PubMed (December 7th, 2022). Inclusion criteria include the randomized controlled trials (RCTs) participated by those diagnosed with COVID-19 and treated with essential oils as adjuvant therapy. Quality assessment was carried out using Cochrane ‘risk-of-bias’ 2.0 tool. A total of 2112 records were retrieved from the initial screening, which was reduced to four publications (n=344 individuals). The foregoing studies reported that essential oils could improve the recovery rate, alleviate post-COVID-19 fatigue, and prevent disease progression. Regarding their potential antiviral activity, better designed studies are needed. In conclusion, essential oils as adjuvant therapy are beneficial in ameliorating mild COVID-19 symptoms.